[Assessment of a pharmaceutical interventional programme in patients on medications with renal risk]
| Autor: | L, Alvarez Arroyo, E, Climent Grana, N, Bosacoma Ros, S, Roca Meroño, M, Perdiguero Gil, J P, Ordovás Baines, J, Sánchez Payá |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Adult
Aged 80 and over Male Drug-Related Side Effects and Adverse Reactions Comorbidity Middle Aged Kidney Drug Costs Anti-Bacterial Agents Cross-Sectional Studies Pharmaceutical Preparations Cost Savings Humans Kidney Failure Chronic Patient Compliance Female Kidney Diseases Prospective Studies Aged |
| Zdroj: | Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria. 33(3) |
| ISSN: | 1130-6343 |
| Popis: | To compare the adaptation of medical prescriptions according to the dosage guides in patients with renal disease, before and after applying a pharmaceutical intervention programme. The secondary objectives were to prepare a guide to dosing in renal disease and to measure the prevalence of prescription of drugs with renal risk.Non-randomised, experimental interventional study (before/after) conducted in a general hospital with 800 beds, including hospitalised patients, over the age of 18, with kidney disease and drugs with renal risk prescribed in their pharmacotherapeutic profile. The study was designed to be carried out in two descriptive cross-cutting phases (control group) and a prospective interventional cohort study (intervention group). The primary variable was the percentage non-adaptation according to the stage of renal disease.The study included 185 patients, 88 in the control group and 97 in the intervention group. In the intervention group, the prevalence of non-compliance before and after the intervention was 18.7 % and 2.1 %, representing a statistically significant reduction in non-adaptation of the dose. The costs saved with the pharmaceutical intervention programme were 1,939.63 euro over two months, the average saving per medication intervened amounting to 62.57 euro (CI 95 %, 23.99-101.14 euro; p = 0.02).The results of the study indicate that the application of a pharmaceutical care model based on the prospective validation of drugs with renal risk, very significantly improved the adaptation of dosing regimens in kidney disease. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|